发明名称 |
Therapeutical use of antibody inducing the production of cytokines |
摘要 |
<p>Use of an optimized chimeric humanized or human monoclonal antibody (MAb) to produce a composition for treating disease in which: (a) the number of antigen sites (antigenic density) is low or the antigens are poorly accessible to antibodies; or (b) the number of effector cells (EC) activated or recruited is low. Use of an optimized chimeric humanized or human monoclonal antibody (MAb) to produce a composition for treating disease in which: (a) the number of antigen sites (antigenic density) is low or the antigens are poorly accessible to antibodies; or (b) the number of effector cells (EC) activated or recruited is low. MAb has a glycan structure generally of the 'two-antennae' type, with short chains, low level of silylation of mannose and GlcNAc at the non-intercalated terminal points of attachment, low level of fucosylation and non-zero level of intermediate GlcNAc. ACTIVITY : Cytostatic; Hematological; Antibacterial; Parasiticide. No details of tests for these activities are given. MECHANISM OF ACTION : Immunotherapy; inducing stimulation of cytokine secretion and thus antibody-dependent cellular cytotoxicity.</p> |
申请公布号 |
EP2092939(A2) |
申请公布日期 |
2009.08.26 |
申请号 |
EP20090152731 |
申请日期 |
2003.09.15 |
申请人 |
LFB BIOTECHNOLOGIES |
发明人 |
DE ROMEUF, CHRISTOPHE;GAUCHER, CHRISTINE;GLACET, ARNAUD;DHAINAUT, FREDERIC;BOUREL, DOMINIQUE;BIHOREAU, NICOLAS;NONY, EMMANUEL |
分类号 |
G01N33/68;A61K39/395;C07K16/28;C12Q1/02;G01N33/50;G01N33/53;G01N33/80 |
主分类号 |
G01N33/68 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|